CAMK2G and allergic asthma: In this regard, Morris et al. proposed the inhibition of inflammation-mediating Ca2+/calmodulin-dependent protein kinase (CaMKII), localized in the bronchial epithelium of asthma patients, by inhaled administration of polylactide-co-glycolide (PLGA)-based cationic nanoparticles with CaMKII-inhibitory peptide (CaMKIIN) and demonstrated a reduction in the severity of allergic asthma in a mouse model [139].